MX2017005663A - Tetrahidropiranos sustituidos y metodo de uso. - Google Patents

Tetrahidropiranos sustituidos y metodo de uso.

Info

Publication number
MX2017005663A
MX2017005663A MX2017005663A MX2017005663A MX2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A
Authority
MX
Mexico
Prior art keywords
compounds
formula
methods
substituted tetrahydropyrans
compositions
Prior art date
Application number
MX2017005663A
Other languages
English (en)
Inventor
R Kym Philip
B Searle Xenia
Liu Bo
C Yeung Ming
WANG Xueqinq
Original Assignee
Abbvie Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Sarl filed Critical Abbvie Sarl
Publication of MX2017005663A publication Critical patent/MX2017005663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la fórmula (I): (ver Fórmula) y las sales farmacéuticamente aceptables o las formas radiomarcadas de los mismos, en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 y m son como se definen en la memoria descriptiva, son útiles en el tratamiento de las afecciones o los trastornos que sean prevenidos o mitigados por la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR). Se describen los métodos para la elaboración de los compuestos. También se describen composiciones farmacéuticas de los compuestos de la fórmula (I) y los métodos para utilizar estos compuestos y composiciones.
MX2017005663A 2014-10-31 2015-10-29 Tetrahidropiranos sustituidos y metodo de uso. MX2017005663A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462073586P 2014-10-31 2014-10-31
PCT/US2015/058043 WO2016069891A1 (en) 2014-10-31 2015-10-29 Substituted tetrahydropyrans and method of use

Publications (1)

Publication Number Publication Date
MX2017005663A true MX2017005663A (es) 2018-03-01

Family

ID=55851906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005663A MX2017005663A (es) 2014-10-31 2015-10-29 Tetrahidropiranos sustituidos y metodo de uso.

Country Status (10)

Country Link
US (1) US9567322B2 (es)
EP (1) EP3212184B1 (es)
JP (1) JP6615213B2 (es)
CN (1) CN107427490A (es)
AU (1) AU2015339196A1 (es)
BR (1) BR112017009194A2 (es)
CA (1) CA2966023A1 (es)
MX (1) MX2017005663A (es)
TW (1) TW201625599A (es)
WO (1) WO2016069891A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (zh) 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
US9840513B2 (en) * 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
WO2017060879A1 (en) 2015-10-09 2017-04-13 AbbVie S.à.r.l. Novel compounds for treatment of cystic fibrosis
PL3359541T3 (pl) 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
EP3359539A1 (en) 2015-10-09 2018-08-15 AbbVie S.À.R.L. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
CN110483457A (zh) * 2018-05-14 2019-11-22 上海迈法生物科技有限公司 4-氨基四氢吡喃的一锅法合成工艺
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2021011327A1 (en) 2019-07-12 2021-01-21 Orphomed, Inc. Compound for treating cystic fibrosis
CA3157798A1 (en) 2019-11-12 2021-05-20 Zhongli Gao 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
AU2023338225A1 (en) 2022-09-07 2025-03-20 Genzyme Corporation Macrocyclic compounds, compositions, and methods of using thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200603515B (en) * 2003-10-08 2007-11-28 Vertex Pharma Modulators of ATP-binding cassette transporters
WO2005120497A2 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
AU2008256717B2 (en) 2007-05-25 2013-11-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
WO2009076593A1 (en) 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EA201000675A1 (ru) * 2007-12-18 2011-06-30 Гленмарк Фармасьютикалс, С.А. Производные хромана как модуляторы trpv3
DK2615085T3 (en) * 2008-03-31 2015-10-05 Vertex Pharma Pyridyl derivatives as CFTR modulators
AU2009276699A1 (en) * 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
EP2358680B1 (en) 2008-10-23 2013-03-20 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
NZ602795A (en) * 2010-04-07 2015-01-30 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
CN105307655B (zh) 2013-03-13 2019-05-03 弗拉特利发现实验室有限责任公司 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
AU2015229188A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity

Also Published As

Publication number Publication date
US20160122331A1 (en) 2016-05-05
CN107427490A (zh) 2017-12-01
CA2966023A1 (en) 2016-05-06
TW201625599A (zh) 2016-07-16
JP2017533277A (ja) 2017-11-09
EP3212184A1 (en) 2017-09-06
BR112017009194A2 (pt) 2017-12-26
EP3212184A4 (en) 2018-07-04
JP6615213B2 (ja) 2019-12-04
EP3212184B1 (en) 2020-04-01
WO2016069891A1 (en) 2016-05-06
AU2015339196A1 (en) 2017-05-11
US9567322B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
GEP20247634B (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
GEP20217329B (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
BR112017009194A2 (pt) tetra-hidropiranos substituídos e método de uso
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
SG10201902963PA (en) Modulators of cystic fibrosis transmembrane conductance regulator
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MY190429A (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
CR20200157A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
NZ750187A (en) Pyridone amides as modulators of sodium channels
MY193728A (en) Muscarinic receptor agonists
MX2015009270A (es) Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
TW201613864A (en) Novel compounds
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX2016009581A (es) Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso.
WO2017177004A8 (en) Tertiary amides and method of use
MD20170011A2 (ro) Compuşi imidazopiridazinici
PH12017500595A1 (en) Aldosterone synthase inhibitors
MX2017002775A (es) Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
MY193041A (en) Novel fused imidazobenzothiazole compounds
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators